Lineage Cell Therapeutics, Inc. Annual Return On Assets in % from 2012 to 2023

Taxonomy & unit
ratio: %
Description
Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Return On Assets history and growth rate from 2012 to 2023.
  • Lineage Cell Therapeutics, Inc. Return On Assets for the quarter ending September 30, 2024 was -19.7 %, a 3.06% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Return On Assets for 2023 was -19.9 %, a 1.32% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Return On Assets for 2022 was -19.6 %, a 35.1% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Return On Assets for 2021 was -30.3 %, a 62% decline from 2020.
Return On Assets, Annual (%)
Return On Assets, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -19.9 -0.26 -1.32% Jan 1, 2023 Dec 31, 2023
2022 -19.6 +10.6 +35.1% Jan 1, 2022 Dec 31, 2022
2021 -30.3 -11.6 -62% Jan 1, 2021 Dec 31, 2021
2020 -18.7 -10.8 -137% Jan 1, 2020 Dec 31, 2020
2019 -7.89 +28.9 +78.6% Jan 1, 2019 Dec 31, 2019
2018 -36.8 -26.7 -265% Jan 1, 2018 Dec 31, 2018
2017 -10.1 -38.4 -136% Jan 1, 2017 Dec 31, 2017
2016 28.3 +86.9 Jan 1, 2016 Dec 31, 2016
2015 -58.6 -1.36 -2.38% Jan 1, 2015 Dec 31, 2015
2014 -57.2 +50 +46.6% Jan 1, 2014 Dec 31, 2014
2013 -107 -46 -75.1% Jan 1, 2013 Dec 31, 2013
2012 -61.2 Jan 1, 2012 Dec 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.